Noteworthy Price Action: Could Eagle Pharmaceuticals Inc Rise Even More? The Stock Had Another Big Increase Today

Noteworthy Price Action: Could Eagle Pharmaceuticals Inc Rise Even More? The Stock Had Another Big Increase Today

The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) is a huge mover today! About 346,941 shares traded hands. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 78.02% since April 4, 2016 and is uptrending. It has outperformed by 76.93% the S&P500.
The move comes after 6 months positive chart setup for the $1.17B company. It was reported on Nov, 4 by Barchart.com. We have $89.77 PT which if reached, will make NASDAQ:EGRX worth $234.00M more.

Analysts await Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to report earnings on November, 9. They expect $0.84 EPS, up 229.23% or $1.49 from last year’s $-0.65 per share. EGRX’s profit will be $13.14 million for 22.26 P/E if the $0.84 EPS becomes a reality. After $0.80 actual EPS reported by Eagle Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 5.00% EPS growth.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Ratings Coverage

Out of 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Eagle Pharma has been the topic of 9 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets with “Outperform” on Tuesday, May 10. The rating was downgraded by Mizuho to “Neutral” on Monday, June 20. Mizuho initiated Eagle Pharmaceuticals Inc (NASDAQ:EGRX) on Wednesday, December 9 with “Buy” rating. As per Wednesday, July 29, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating by Mizuho given on Thursday, November 3. On Friday, February 26 the stock rating was maintained by Mizuho with “Buy”. The stock has “Buy” rating given by Mizuho on Wednesday, October 26. As per Wednesday, November 2, the company rating was maintained by William Blair. The rating was maintained by RBC Capital Markets with “Outperform” on Thursday, November 3.

According to Zacks Investment Research, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.”

More recent Eagle Pharmaceuticals Inc (NASDAQ:EGRX) news were published by: Fool.com which released: “Why Eagle Pharmaceuticals, Inc. Is Soaring 21.6% Today” on November 02, 2016. Also Businesswire.com published the news titled: “Final Reminder: Eagle Pharmaceuticals to Host 2016 Investor Day in New York City” on November 01, 2016. Zacks.com‘s news article titled: “Will Eagle Pharmaceuticals (EGRX) Continue to Surge Higher?” with publication date: November 04, 2016 was also an interesting one.

EGRX Company Profile

Eagle Pharmaceuticals, Inc., incorporated on January 2, 2007, is a specialty pharmaceutical company. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). The Firm has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). The Company’s near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment